| Autor: |
Sorio, R. Roemer-Becuwe, C. Hilpert, F. Gibbs, E. García, Y. Kaern, J. Huizing, M. Witteveen, P. Zagouri, F. Coeffic, D. Lück, H.-J. González-Martín, A. Kristensen, G. Levaché, C.-B. Lee, C.K. Gebski, V. Pujade-Lauraine, E. |
| Jazyk: |
angličtina |
| Rok vydání: |
2017 |
| ISSN: |
0097-6911 |
| Popis: |
Background The AURELIA trial demonstrated significantly improved progression-free survival (PFS) with bevacizumab added to chemotherapy for platinum-resistant ovarian cancer (PROC). Methods Patients with PROC were randomised to receive investigator-selected single-agent chemotherapy alone or with bevacizumab. Post-hoc exploratory analyses assessed efficacy, safety and patient-reported outcomes according to age |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
